Bharat Parenter.

Which are the latest news on Bharat Parenter.?

Why is Bharat Parenterals Ltd falling/rising?

As of 05-Sep, Bharat Parenterals Ltd's stock price is Rs 1,527.95, down 0.46% with a recent decline in trading activity and investor interest. Despite a year-to-date increase of 26.33%, the stock has faced consecutive losses over the past two days.

As of 05-Sep, Bharat Parenterals Ltd's stock price is currently at Rs 1,527.95, reflecting a decrease of Rs 7.0 or 0.46%. The stock has been experiencing a consecutive decline over the past two days, with a total drop of 1.37% during this period. Additionally, the stock touched an intraday low of Rs 1,480, which represents a significant decline of 3.58% from its previous levels.<BR><BR>Investor participation appears to be falling, as evidenced by a delivery volume of 1.01 k on September 3, which is down by 45.63% compared to the 5-day average delivery volume. This decline in trading activity may indicate reduced interest among investors, contributing to the stock's downward movement.<BR><BR>Despite these recent challenges, it is noteworthy that the stock has performed well over longer periods, with a year-to-date increase of 26.33% and a 3-year increase of 154.66%. However, the current performance aligns with a broader trend where the stock has been losing value recently, which is reflected in the current price movement.

Who are in the management team of Bharat Parenter.?

The management team of Bharat Parenter includes Bharat Kumar R Desai (Managing Director), Hemang Jayendrabhai Shah, Shaileshkumar Ghabhawala, Sanjay Shah (Directors), and independent directors Zankhana Sheth and Mukesh Patel.

The management team of Bharat Parenter includes the following individuals:<BR><BR>1. **Bharat Kumar R Desai** - Managing Director<BR>2. **Hemang Jayendrabhai Shah** - Director<BR>3. **Shaileshkumar Ghabhawala** - Director<BR>4. **Zankhana Sheth** - Independent Director<BR>5. **Mukesh Patel** - Independent Director<BR>6. **Sanjay Shah** - Director<BR><BR>If you need more information about their roles or the company's activities, feel free to ask!

What does Bharat Parenter. do?

Bharat Parenterals Ltd. manufactures drugs, pharmaceutical formulations, and ayurvedic products, operating as a Micro Cap company in the Pharmaceuticals & Biotechnology industry. As of June 2026, it reported net sales of 94 Cr and a net profit of 1 Cr.

Overview:<BR>Bharat Parenterals Ltd. is engaged in the manufacturing of drugs, pharmaceutical formulations, and ayurvedic products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in September 1992 in Gujarat, Bharat Parenterals Ltd. was promoted by Ramesh Desai and Bharat Desai. The latest financial results reported are for the quarter ending June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 94 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 1,077 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.06%<BR>- Debt Equity: 0.40<BR>- Return on Equity: -2.54%<BR>- Price to Book: 3.30<BR><BR>Contact Details:<BR>- Address: Survey No 144 & 146 Haripura, Jarod Samlaya Road Tal Savli Vadodara Gujarat : 391520<BR>- Tel: 91-2667-251679<BR>- Email: cs@bplindia.in/info@bplindia.in<BR>- Website: http://www.bplindia.in

Who are the peers of the Bharat Parenter.?

Bharat Parenter.'s peers include Sigachi Industries, Lincoln Pharma, Themis Medicare, Bajaj Healthcare, Kopran, Wanbury, Anlon Healthcare, Anuh Pharma, and Amanta Healthcare. Bharat Parenter. has below average management risk and growth, with a 1-year return of 12.71%, compared to peers like Kopran (40.77%) and Bajaj Healthcare (-21.10%).

Peers: The peers of Bharat Parenter. are Sigachi Indust., Lincoln Pharma., Themis Medicare, Bajaj Healthcare, Kopran, Wanbury, Anlon Healthcare, Anuh Pharma, and Amanta Healthcar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anlon Healthcare and Anuh Pharma, while Average management risk is found at Sigachi Indust., Lincoln Pharma., Themis Medicare, Bajaj Healthcare, Kopran, Wanbury, and Amanta Healthcar, and the rest. Bharat Parenter. has Below Average management risk. Growth is Excellent at Anlon Healthcare, while Average growth is noted at Wanbury and the rest, and Below Average growth is seen at Sigachi Indust., Lincoln Pharma., Themis Medicare, Bajaj Healthcare, Kopran, Bharat Parenter., Anuh Pharma, and Amanta Healthcar. Capital Structure is Excellent at Anuh Pharma, Good at Kopran and Anlon Healthcare, and Below Average at Bharat Parenter., Themis Medicare, Bajaj Healthcare, Wanbury, and Amanta Healthcar, while Excellent capital structure is observed at Sigachi Indust. and Lincoln Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kopran at 40.77%, while the lowest is Bajaj Healthcare at -21.10%. Bharat Parenter.'s 1-year return is 12.71%, which is higher than Bajaj Healthcare but lower than Kopran. Notably, Wanbury has a negative six-month return of 0.75%.

How big is Bharat Parenter.?

As of 31st August, Bharat Parenterals Ltd has a market capitalization of 1,077.00 Cr, with Net Sales of 323.17 Cr and a Net Profit loss of 15.41 Cr over the latest four quarters. Shareholder's Funds are 330.67 Cr and Total Assets are valued at 647.70 Cr as of March 2025.

As of 31st August, Bharat Parenterals Ltd has a market capitalization of 1,077.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bharat Parenterals reported Net Sales of 323.17 Cr. However, the company experienced a loss of 15.41 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 330.67 Cr and Total Assets were valued at 647.70 Cr.

Should I buy, sell or hold Bharat Parenterals Ltd?

When is the next results date for Bharat Parenterals Ltd?

The next results date for Bharat Parenterals Ltd is August 5, 2026.

The next results date for Bharat Parenterals Ltd is scheduled for August 5, 2026.

Are Bharat Parenterals Ltd latest results good or bad?

Bharat Parenterals Ltd's latest results are concerning, showing a consolidated net loss of ₹4.80 crore in Q4 FY26 despite a 52.81% increase in net sales from the previous quarter. Overall, the company faces significant operational challenges, with a full-year net loss of ₹43 crore and a weak return on equity of 6.41%.

Bharat Parenterals Ltd's latest results indicate a challenging situation for the company. In the fourth quarter of FY26, the company reported a consolidated net loss of ₹4.80 crore, which, while representing a lower loss compared to the previous quarter, still reflects ongoing financial difficulties. <BR><BR>Net sales for the quarter were ₹99.62 crore, showing a significant sequential increase of 52.81% from the previous quarter. However, this figure is down 4.19% year-on-year, indicating a decline in revenue compared to the same period last year. The operating margin, excluding other income, was negative at -0.53%, marking the lowest operating profitability in recent quarters. This decline in operating margin is concerning, especially given the previous year's operating margin of 11.88% in Q1 FY25.<BR><BR>The full fiscal year FY25 was particularly troubling, with a consolidated net loss of ₹43 crore on revenues of ₹340 crore, a stark contrast to a profit of ₹10 crore in FY24. The company's return on equity (ROE) stands at a weak 6.41%, indicating poor capital efficiency.<BR><BR>Overall, while there is a slight improvement in the net loss on a quarter-over-quarter basis, the underlying operational challenges and persistent losses suggest that the results are more bad than good. The company is facing significant hurdles that need to be addressed to achieve a turnaround.

Is Bharat Parenter. technically bullish or bearish?

As of December 4, 2025, Bharat Parenter's technical outlook is bearish, indicated by a bearish MACD, moving averages, and KST, along with mildly bearish Bollinger Bands, suggesting a consolidation phase without a clear trend.

As of 4 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Additionally, Bollinger Bands are indicating a mildly bearish trend on both weekly and monthly time frames. The lack of signals from the RSI and Dow Theory suggests a consolidation phase without a clear trend. Overall, the technical outlook for Bharat Parenter is bearish.

How has been the historical performance of Bharat Parenter.?

Bharat Parenter has experienced significant revenue growth, with net sales rising from INR 204.64 crore in March 2021 to INR 340.38 crore in March 2025. However, rising costs have led to declining profitability, resulting in a net loss of -INR 12.63 crore in March 2025.

Answer:<BR>The historical performance of Bharat Parenter shows significant fluctuations in key financial metrics over the years, culminating in a challenging fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Bharat Parenter's net sales have shown a steady increase from INR 204.64 crore in March 2021 to INR 340.38 crore in March 2025, reflecting a strong growth trajectory. However, total operating income followed a similar trend, reaching INR 340.38 crore in March 2025, up from INR 261.22 crore in March 2024. Despite this growth in revenue, the company faced rising raw material costs, which increased from INR 127.13 crore in March 2021 to INR 178.17 crore in March 2025. Consequently, total expenditure also rose significantly, leading to an operating profit (PBDIT) of only INR 2.70 crore in March 2025, a sharp decline from INR 27.08 crore in March 2024. This decline in profitability is further highlighted by a profit before tax of -INR 33.95 crore in March 2025, compared to a profit of INR 18.72 crore in March 2024. The net profit also turned negative, recording -INR 12.63 crore in March 2025, down from a profit of INR 14.51 crore in March 2024. On the balance sheet, total liabilities increased to INR 647.70 crore in March 2025 from INR 503.93 crore in March 2024, while total assets rose to INR 647.70 crore, indicating a growing leverage position. Cash flow from operating activities turned negative at -INR 4.00 crore in March 2024, contrasting with the previous year's positive cash flow. Overall, while Bharat Parenter has achieved revenue growth, it has struggled with profitability and rising costs, leading to a challenging financial position in recent years.

Who are the top shareholders of the Bharat Parenter.?

The top shareholder of Bharat Parenter is Desai Shares And Stock Private Limited, holding 39.63%. Other notable shareholders include Asoj Soft Caps Pvt Ltd at 4.94% and individual investors with a collective stake of 19.31%.

The top shareholders of Bharat Parenter include Desai Shares And Stock Private Limited, which holds the highest promoter stake at 39.63%. The company has no pledged promoter holdings, and there is one foreign institutional investor (FII) holding 0.11%. The highest public shareholder is Asoj Soft Caps Pvt Ltd, with a stake of 4.94%. Additionally, individual investors collectively hold 19.31% of the company's shares.

Is Bharat Parenter. overvalued or undervalued?

As of August 9, 2024, Bharat Parenterals Ltd. is considered risky and overvalued, with alarming financial metrics such as a PE ratio of -73.55 and an EV to EBITDA ratio of 385.93, despite recent stock performance outpacing the Sensex.

As of 9 August 2024, Bharat Parenterals Ltd. has moved from a valuation grade of very expensive to risky, indicating a significant shift in its perceived value. The company is currently deemed overvalued, particularly highlighted by its PE ratio of -73.55 and an EV to EBITDA ratio of 385.93, which are both alarming figures suggesting substantial concerns regarding profitability and valuation metrics. Additionally, the Price to Book Value stands at 2.81, further reinforcing the notion of overvaluation.<BR><BR>In comparison to its peers, Bharat Parenterals Ltd. shows a stark contrast; for instance, its PE ratio is significantly worse than the industry average, and the EV to EBITDA ratio is exceedingly high compared to typical benchmarks. The company's recent stock performance has outpaced the Sensex over the past week and month, with returns of 9.29% and 24.85% respectively, but this does not mitigate the underlying valuation concerns. Overall, the financial metrics indicate that Bharat Parenterals Ltd. is not only risky but also overvalued in the current market landscape.

Has Bharat Parenter. declared dividend?

Bharat Parenterals Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of June 25, 2024. Recent total returns show a -22.1% return over the last 6 months, while longer-term returns have been more favorable, with a total return of 396.85% over the past 5 years.

Bharat Parenterals Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 25 Jun 24<BR><BR>Dividend Yield: 0.07%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.1%, with a dividend return of 0%, resulting in a total return of -22.1%.<BR><BR>Over the past year, the price return was -2.33%, the dividend return was 0.07%, leading to a total return of -2.26%.<BR><BR>In the 2-year period, the price return was 262.84%, the dividend return was 0.45%, culminating in a total return of 263.29%.<BR><BR>For the 3-year period, the price return stood at 273.76%, with a dividend return of 0.53%, resulting in a total return of 274.29%.<BR><BR>In the 4-year period, the price return was 200.0%, the dividend return was 0.47%, leading to a total return of 200.47%.<BR><BR>Over the last 5 years, the price return was 396.26%, with a dividend return of 0.59%, resulting in a total return of 396.85%.<BR><BR>Overall, Bharat Parenterals Ltd has declared a dividend, but the recent total returns indicate significant fluctuations, particularly in the short term, while longer-term returns have been more favorable.